Congenital Hyperinsulinism Treatment Market Size (7MM) is Projected to Grow at a CAGR of 12% by 2036, estimates DelveInsight

DelveInsight's 'Congenital Hyperinsulinism Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of congenital hyperinsulinism, historical and forecasted epidemiology, as well as the congenital hyperinsulinism market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

To know in detail about the Congenital Hyperinsulinism market outlook, drug uptake, click here @ https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Congenital Hyperinsulinism Market Report
• On July 09, 2026- Zealand Pharma initiated a clinical trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 (NCT04172441) or ZP4207-17109 (NCT03777176) (defined as lead-in trials). The primary objective is to evaluate the long-term safety of dasiglucagon administered as a subcutaneous (SC) infusion in children with CHI.
• The total diagnosed prevalent cases of congenital hyperinsulinism in the 7MM were ~15,700 cases in 2025, which is expected to increase during the forecast period (2026-2036).
• The highest number of prevalent cases was observed in the United States. On the other hand, within the EU4 and the UK, Germany accounted for the highest number of congenital hyperinsulinism cases, with approximately 2,800 cases reported in 2025.
• In Japan, the ABCC8 and KCNJ11 gene mutations have the highest contribution, followed by the other gene mutations.
• In 2025, France reported nearly 1,750 cases of diffuse congenital hyperinsulinism, 360 focal cases, and 165 atypical cases. This distribution highlights the variability of the disorder. Projections suggest these numbers are anticipated to rise by 2036, emphasizing the need for improved diagnostics.
• The leading Congenital Hyperinsulinism Companies such as Zealand Pharma, Rezolute, Hanmi Pharmaceuticals, Crinetics Pharmaceuticals and others.
• Promising Congenital Hyperinsulinism Therapies: Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136, and others.

Get a Free sample for the Congenital Hyperinsulinism Market Report @ https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Congenital Hyperinsulinism Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Congenital Hyperinsulinism
• Type-specific Diagnosed Prevalent Cases of Congenital Hyperinsulinism based on Histological Presentation
• Mutation-specific Diagnosed Prevalent Cases of Congenital Hyperinsulinism
• Total Treated Cases of Congenital Hyperinsulinism

Download the report to understand which factors are driving Congenital Hyperinsulinism epidemiology trends @ https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Congenital Hyperinsulinism Pipeline Analysis
• ZEGALOGUE (dasiglucagon): Zealand Pharma
ZEGALOGUE is a glucagon analog that increases blood glucose by stimulating hepatic glucose release. While approved for severe hypoglycemia in diabetes, it may have relevance in congenital hyperinsulinism due to its ability to counteract hypoglycemia associated with excessive insulin secretion. The drug is currently in the registration phase and expects to resubmit a new drug application (NDA) in 2H 2026.

• Ersodetug (RZ358): Rezolute
Ersodetug is an investigational monoclonal antibody designed to regulate insulin activity by targeting the insulin receptor, thereby helping to stabilize blood glucose levels in congenital hyperinsulinism. It is currently in Phase III clinical development. The drug has received several regulatory designations, like the BTD, the UK's Innovative Licensing and Access Pathway (ILAP), and Orphan Drug Designations (ODD) from the US and Europe union for congenital hyperinsulinism and insulinoma-related hypoglycemia

Congenital Hyperinsulinism Market Outlook
Congenital hyperinsulinism is a rare but serious condition characterized by excessive insulin secretion from pancreatic beta cells, leading to persistent hypoglycemia. Effective treatment aims to maintain stable blood glucose levels, prevent neurological complications, and improve the quality of life. Management strategies can be broadly categorized into pharmacological and non-pharmacological approaches, depending on the severity and type of congenital hyperinsulinism. Pharmacological treatment is the first-line approach for congenital hyperinsulinism in patients who do not require immediate surgery, with the choice of medication depending on genetic factors, treatment response, and hypoglycemia severity. Somatostatin analogues like octreotide and lanreotide inhibit insulin secretion by targeting somatostatin receptors; octreotide is administered subcutaneously or intravenously for patients unresponsive to diazoxide, while lanreotide, a long-acting option, is given monthly for long-term management. However, these drugs may cause gastrointestinal issues, growth suppression, and gallstones.

To know more about Congenital Hyperinsulinism treatment, visit @ Congenital Hyperinsulinism Medications- https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Congenital Hyperinsulinism Therapies and Companies
• Dasiglucagon: Zealand Pharma
• RZ358: Rezolute
• Avexitide: Eiger BioPharmaceuticals
• CRN04777: Crinetics
• ABG-023: AmideBio
• HM15136: Hanmi pharmaceutical

Congenital Hyperinsulinism Treatment Landscape
Pharmacological treatment is the first-line approach for congenital hyperinsulinism in patients who do not require immediate surgery, with the choice of medication depending on genetic factors, treatment response, and hypoglycemia severity. Somatostatin analogues like Octreotide and lanreotide inhibit insulin secretion by targeting somatostatin receptors; Octreotide is administered subcutaneously or intravenously for patients unresponsive to diazoxide, while lanreotide, a long-acting option, is given monthly for long-term management. However, these drugs may cause gastrointestinal issues, growth suppression, and gallstones. Glucagon therapy is used in acute hypoglycemic episodes, where it increases blood glucose by stimulating hepatic glycogen breakdown, and can be administered via injection or continuous infusion in emergency settings. Emergency care primarily includes intravenous glucose and glucagon infusion, while diazoxide and somatostatin analogues are used for ongoing control rather than acute management. Severe or refractory cases may require partial pancreatectomy.

Explore More Insights into the Congenital Hyperinsulinism Therapeutics Market Report- https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Congenital Hyperinsulinism Market Report
• Coverage: 7MM
• Study Period: 2022-2036
• Forecast Period- 2026-2036
• Congenital Hyperinsulinism Companies: Zealand Pharma, Rezolute, Hanmi Pharmaceuticals, Crinetics Pharmaceuticals and others.
• Congenital Hyperinsulinism Therapies: Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136, and others
• Congenital Hyperinsulinism Therapeutic Assessment: Congenital Hyperinsulinism current marketed and Congenital Hyperinsulinism emerging therapies
• Congenital Hyperinsulinism Market Dynamics: Congenital Hyperinsulinism market drivers and Congenital Hyperinsulinism market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Congenital Hyperinsulinism Unmet Needs, KOL's views, Analyst's views, Congenital Hyperinsulinism Market Access and Reimbursement

Discover more about therapies set to grab major Congenital Hyperinsulinism market share @ Congenital Hyperinsulinism market forecast- https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Congenital Hyperinsulinism Market Report Introduction
2. Executive Summary for Congenital Hyperinsulinism
3. SWOT analysis of Congenital Hyperinsulinism
4. Congenital Hyperinsulinism Patient Share (%) Overview at a Glance
5. Congenital Hyperinsulinism Market Overview at a Glance
6. Congenital Hyperinsulinism Disease Background and Overview
7. Congenital Hyperinsulinism Epidemiology and Patient Population
8. Country-Specific Patient Population of Congenital Hyperinsulinism
9. Congenital Hyperinsulinism Current Treatment and Medical Practices
10. Congenital Hyperinsulinism Unmet Needs
11. Congenital Hyperinsulinism Emerging Therapies
12. Congenital Hyperinsulinism Market Outlook
13. Country-Wise Congenital Hyperinsulinism Market Analysis (2019-2032)
14. Congenital Hyperinsulinism Market Access and Reimbursement of Therapies
15. Congenital Hyperinsulinism Market Drivers
16. Congenital Hyperinsulinism Market Barriers
17. Congenital Hyperinsulinism Appendix
18. Congenital Hyperinsulinism Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.